Generic Name: mytomycin
Drug Class: Chemotherapy Medications
Approval Status: Approved
Generic Version Available: No
Jelmyto is an alkylating drug approved for the treatment of low-grade urothelial cancer in the upper urinary tract.
Jelmyto is an alkylating agent that binds to DNA and interferes with transcription factors that play a role in cancer cell growth. In the OLYMPUS trial, 58% of participants treated with Jelmyto experienced complete remission. Jelmyto was first approved in 1974.
Jemlyto is inserted into the urinary tract through a catheter once weekly for six weeks and then once monthly.
The most common adverse reactions include ureter obstruction, abdominal or flank pain, urinary tract infections, difficult urination, blood in the urine, kidney dysfunction, nausea and vomiting. Jelmyto can cause depletion of white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. It can cause fetal harm if used during pregnancy.
For More Info: https://www.jelmyto.com/hcp/
Patient Assistance Program Info: https://www.jelmyto.com/patient/resources/
Last Reviewed: December 29, 2020